Clinical efficacy and cost-effectiveness of rosuvastatin.


Rosuvastatin, which was approved by the FDA in 2003 and has been available in Europe since 2002, is the newest and most efficacious of the currently available 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins). More than 8 million patients have now been treated with rosuvastatin for up to 3 years, and initial concerns about the… (More)
DOI: 10.1586/14737167.7.1.31